Description
GSK-1292263 is a novel GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GSK1292263 improves glucose regulation in animal models of diabetes, but has no effect on plasma glucose in type 2 diabetics.
GSK-1292263 is a novel GPR119 receptor agonist and is used for the treatment of type 2 diabetes. GSK1292263 improves glucose regulation in animal models of diabetes, but has no effect on plasma glucose in type 2 diabetics.
Alternate Name/Synonyms: 3-isopropyl-5-(4-(((6-(4-(methylsulfonyl)phenyl)pyridin-3-yl)oxy)methyl)piperidin-1-yl)-1,2,4-oxadiazole
Appearance: Crystalline solid
Formulation: N/A
CAS Number: 1032823-75-8
Structure Available?: Yes
Peptide sequence: N/A
Salt Form: N/A
Molecular Formula: C₂₃H₂₈N₄O₄S
Molecular Weight: 456.56
Cell-Permeable?: Yes
Purity: ≥98% by HPLC
Solubilities: DMSO (>5 mg/ml)
Handling: Protect from air and light
Country of Origin: USA
Tag Line: A novel GPR119 receptor agonist
MDL Number: N/A
PubChem CID: 24996872
SMILES: CC(C)C1=NOC(=N1)N2CCC(CC2)COC3=CN=C(C=C3)C4=CC=C(C=C4)S(=O)(=O)C
InChi: InChI=1S/C23H28N4O4S/c1-16(2)22-25-23(31-26-22)27-12-10-17(11-13-27)15-30-19-6-9-21(24-14-19)18-4-7-20(8-5-18)32(3,28)29/h4-9,14,16-17H,10-13,15H2,1-3H3
InChi Key: AYJRTVVIBJSSKN-UHFFFAOYSA-N
Additional Information
Storage Condition: |
-20°C |
Shipping Condition: |
Gel Pack |
Shelf Life: |
36 months |